Welcome to Men's Health Focus.
Please log in or register to view the content of this site.
This website provides free access to a range of men’s health related resources and has been developed by EPG Online with an educational grant and assistance from Bayer HealthCare Pharmaceuticals. The content of this site is intended for doctors and other healthcare professionals.
As a disease topic Men's Health covers a broad set of issues affecting men of all ages. Some of the issues requiring greater focus and more thorough dissemination of information amongst the healthcare community, are those that have the potential to go undetected in the early stages. These include, hypogonadism and erectile dysfunction.
Early detection and more regular health checks of these diseases, not only improve prognosis and efficacy of treatment outcomes, but also quality of life.
- January 2014 - Testosterone replacement therapy can improve metabolic and sexual parameters in men with type 2 diabetes
- Men in the BLAST study were divided into MILD (testosterone 8.1−12 nmol/L) or SEVERE (testosterone <8.0 nmol/L) groups according to baseline testosterone levels
- Increases in testosterone levels after 30 weeks were greater in the SEVERE group than the MILD group (2.20 vs. 1.47 nmol/L, measured as trough levels prior to the next injection)
- After 30 weeks’ treatment with testosterone undecanoate (TU) 1,000 mg, only the SEVERE group showed significant improvements in sexual function (erectile function, p=0.029; intercourse satisfaction, p=0.020; sexual desire, p<0.001)
- Only the MILD group showed improvements in metabolic and psychological parameters (weight, p=0.003; BMI, p=0.002; waist circumference, p<0.001; Hospital Anxiety and Depression Score [HADS], p=0.007)
- The presence of baseline depression (HADS ≥11) reduced the response of metabolic parameters to TU
- TU significantly reduced HbA1c in men with T2DM, particularly in men with poorly controlled diabetes
- HbA1c was significantly reduced by 6 weeks and maintained at 18 weeks (both p=0.007)
- In men with baseline HbA1c ≥7.5%, TU reduced HbA1c by 0.41% at 6 weeks, and this level was maintained at 30 weeks
- TU significantly improved subjective measurements of general health at 30 weeks (p<0.001)
- Testosterone level thresholds may exist, with improvement of sexual and metabolic parameters dependent on achieving certain levels of testosterone, and all symptoms improving at trough levels ≥12 nmol/L
- Target testosterone trough levels of 15 nmol/L and improvements in symptoms were only achieved after 12 months’ treatment, suggesting that a period of 3−6 months recommended by current guidelines is insufficient and 12−18 months’ treatment are required to attain target therapeutic levels
If you are a healthcare professional and would like to gain free access to menshealthfocus.com you must register or login with your EPG Online username and password.
For your information, the menshealthfocus.com website concentrates on the understanding, management and treatment of erectile dysfunction and hypogonadism. The website also provides extensive details on up-coming conferences as well as an extensive library of useful resource.
THIS WEBSITE (www.menshealthfocus.com) IS OWNED AND OPERATED BY EPG HEALH MEDIA (EUROPE) LTD.